Evidence map›Paper›PMID 26599802›Full record

ArticleRadiology2016

Gliomas: Motexafin Gadolinium-enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins.

Longhua Qiu, Feng Zhang, Yaoping Shi, Zhibin Bai, Jianfeng Wang, Yonggang Li, Donghoon Lee, Christopher Ingraham, Xiaoyuan Feng, Xiaoming Yang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Longhua QiuFrom the Image-Guided Biomolecular Intervention Research, Department of Radiology, University of Washington School of Medicine, 850 Republican St, Seattle, WA 98109 (L.Q., F.Z., Y.S., Z.B., J.W., Y.L., D.L., C.I., X.Y.); and Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China (L.Q., X.F.).
Feng ZhangFrom the Image-Guided Biomolecular Intervention Research, Department of Radiology, University of Washington School of Medicine, 850 Republican St, Seattle, WA 98109 (L.Q., F.Z., Y.S., Z.B., J.W., Y.L., D.L., C.I., X.Y.); and Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China (L.Q., X.F.).
Yaoping ShiFrom the Image-Guided Biomolecular Intervention Research, Department of Radiology, University of Washington School of Medicine, 850 Republican St, Seattle, WA 98109 (L.Q., F.Z., Y.S., Z.B., J.W., Y.L., D.L., C.I., X.Y.); and Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China (L.Q., X.F.).
Zhibin BaiFrom the Image-Guided Biomolecular Intervention Research, Department of Radiology, University of Washington School of Medicine, 850 Republican St, Seattle, WA 98109 (L.Q., F.Z., Y.S., Z.B., J.W., Y.L., D.L., C.I., X.Y.); and Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China (L.Q., X.F.).
Jianfeng WangFrom the Image-Guided Biomolecular Intervention Research, Department of Radiology, University of Washington School of Medicine, 850 Republican St, Seattle, WA 98109 (L.Q., F.Z., Y.S., Z.B., J.W., Y.L., D.L., C.I., X.Y.); and Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China (L.Q., X.F.).
Yonggang LiFrom the Image-Guided Biomolecular Intervention Research, Department of Radiology, University of Washington School of Medicine, 850 Republican St, Seattle, WA 98109 (L.Q., F.Z., Y.S., Z.B., J.W., Y.L., D.L., C.I., X.Y.); and Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China (L.Q., X.F.).
Donghoon LeeFrom the Image-Guided Biomolecular Intervention Research, Department of Radiology, University of Washington School of Medicine, 850 Republican St, Seattle, WA 98109 (L.Q., F.Z., Y.S., Z.B., J.W., Y.L., D.L., C.I., X.Y.); and Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China (L.Q., X.F.).
Christopher IngrahamFrom the Image-Guided Biomolecular Intervention Research, Department of Radiology, University of Washington School of Medicine, 850 Republican St, Seattle, WA 98109 (L.Q., F.Z., Y.S., Z.B., J.W., Y.L., D.L., C.I., X.Y.); and Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China (L.Q., X.F.).
Xiaoyuan FengFrom the Image-Guided Biomolecular Intervention Research, Department of Radiology, University of Washington School of Medicine, 850 Republican St, Seattle, WA 98109 (L.Q., F.Z., Y.S., Z.B., J.W., Y.L., D.L., C.I., X.Y.); and Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China (L.Q., X.F.).
Xiaoming YangFrom the Image-Guided Biomolecular Intervention Research, Department of Radiology, University of Washington School of Medicine, 850 Republican St, Seattle, WA 98109 (L.Q., F.Z., Y.S., Z.B., J.W., Y.L., D.L., C.I., X.Y.); and Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China (L.Q., X.F.).
Guided Therapeutics (United States) · USUniversity of Washington · USFudan University · CNHuashan Hospital · CN

Funding

Intrabiliary MR/RF-enhanced chemotherapy of malignant biliary obstructionsR01EB012467 · NIBIB · UNIVERSITY OF WASHINGTON · PI YANG, XIAOMING · 2011 to 2015
$5.6M
NIBIB NIH HHS R01 EB012467
6 · The paper itself

Abstract

purposeTo investigate the possibility of using motexafin gadolinium (MGd)-enhanced molecular magnetic resonance (MR) imaging and optical imaging to identify the true margins of gliomas. MATERIALS AND

methodsThe animal protocol was approved by the institutional animal care and use committee. Thirty-six Sprague-Dawley rats with gliomas were randomized into six groups of six rats. Five groups were euthanized 15, 30, 60, 120, and 240 minutes after intravenous administration of 6 mg/kg of MGd, while one group received only saline solution as a control group. After craniotomy, optical imaging and T1-weighted MR imaging were performed to identify the tumor margins. One-way analysis of variance was used to compare optical photon intensity and MR imaging signal-to-noise ratios. Histologic analysis was performed to confirm the intracellular uptake of MGd by tumor cells and to correlate the tumor margins delineated on both optical and MR images.

resultsBoth optical imaging and T1-weighted MR imaging showed tumor margins. The highest optical photon intensity (2.6 × 10(8) photons per second per mm(2) ± 2.3 × 10(7); analysis of variance, P < .001) and MR signal-to-noise ratio (77.61 ± 2.52; analysis of variance, P = .006) were reached at 15-30 minutes after administration of MGd, with continued tumor visibility at 2-4 hours. Examination with confocal microscopy allowed confirmation that the fluorescence of optical images and MR imaging T1 enhancement exclusively originated from MGd that accumulated in the cytoplasm of tumor cells.

conclusionMGd-enhanced optical and MR imaging can allow determination of glioma tumor margins at the optimal time of 15-120 minutes after administration of MGd. Clinical application of these results may allow complete removal of gliomas in a hybrid surgical setting in which intraoperative optical and MR imaging are available.

Indexed as

AnimalsBrain NeoplasmsContrast MediaCraniotomyDisease Models, AnimalGliomaImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMetalloporphyrinsMicroscopy, ConfocalMolecular ImagingRandom AllocationRatsRats, Sprague-DawleySignal-To-Noise RatioContrast MediaMetalloporphyrinsmotexafin gadolinium

Identifiers

PMID26599802
PMCPMC4851136
OpenAlexW2178002579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.